0001387131-23-002560.txt : 20230228 0001387131-23-002560.hdr.sgml : 20230228 20230228161459 ACCESSION NUMBER: 0001387131-23-002560 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230227 FILED AS OF DATE: 20230228 DATE AS OF CHANGE: 20230228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mamoura Diversified Global Holding PJSC CENTRAL INDEX KEY: 0001419351 STATE OF INCORPORATION: C0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40323 FILM NUMBER: 23685477 BUSINESS ADDRESS: STREET 1: P. O. BOX 45005 CITY: ABU DHABI STATE: C0 ZIP: UAE BUSINESS PHONE: 971.2.616.0099 MAIL ADDRESS: STREET 1: P. O. BOX 45005 CITY: ABU DHABI STATE: C0 ZIP: UAE FORMER NAME: FORMER CONFORMED NAME: MUBADALA DEVELOPMENT CO PJSC DATE OF NAME CHANGE: 20071126 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mubadala Investment Co PJSC CENTRAL INDEX KEY: 0001704268 STATE OF INCORPORATION: C0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40323 FILM NUMBER: 23685478 BUSINESS ADDRESS: STREET 1: P.O. BOX 45005 CITY: ABU DHABI STATE: C0 ZIP: 00000 BUSINESS PHONE: 971-2413-0000 MAIL ADDRESS: STREET 1: P.O. BOX 45005 CITY: ABU DHABI STATE: C0 ZIP: 00000 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001601830 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464099738 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 BUSINESS PHONE: (385) 269-0203 MAIL ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 FORMER COMPANY: FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC DATE OF NAME CHANGE: 20140305 4 1 rxrx-form4_022723.xml RXRX - CHANGES IN BENEFICIAL OWNERSHIP X0306 4 2023-02-27 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001704268 Mubadala Investment Co PJSC P.O. BOX 45005 ABU DHABI C0 00000 UNITED ARAB EMIRATES 0 0 1 0 0001419351 Mamoura Diversified Global Holding PJSC P. O. BOX 45005 ABU DHABI C0 UAE UNITED ARAB EMIRATES 0 0 1 0 Class A Common Stock 2023-02-27 4 P 0 52500 7.690 A 12869423 I See Explanation of Responses Class A Common Stock 7062869 I See Explanation of Responses The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.57 to $7.81, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Form 4. Consists of 12,869,423 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP. Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. 6. The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. /s/ Samer Halawa, Chief Legal Officer, Mubadala Investment Company PJSC (6) 2023-02-28 /s/ Samer Halawa, Chief Legal Officer, Mamoura Diversified Global Holdings PJSC (6) 2023-02-28